Status: Not yet recruiting
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis. Participants will receive the Sonrotoclax Plus Dexamethasone regimen with or without Daratumumab for 12 cycles. The Hematologic Response, Organ Response, Survival, and Safety will be evaluated.
Participants needed: 39
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University People's HospitalUpdated: Jan 13, 2026
Eligibility criteria
Patients who meet the diagnostic criteria for Primary Systemic Light Chain Amylo... [+15]
Meets the diagnostic criteria for active multiple myeloma or active lymphoplasma... [+22]